Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data

Abstract : Mutation or epigenetic silencing of homologous recombination (HR) repair genes is characteristic of a growing proportion of triple-negative breast cancers (TNBCs) and high-grade serous ovarian carcinomas. Defects in HR lead to genome instability, allowing cells to acquire the multiple genetic alterations essential for cancer development. However, this deficiency can also be exploited by using DNA damaging agents or by targeting compensatory repair pathways. A noteworthy example is treatment of TNBC and epithelial ovarian cancer harboring BRCA1/2 germline mutations using platinum salts and/or PARP inhibitors. Dramatic responses to PARP inhibitors may support a wider use in the HR-deficient population beyond those with mutated germline BRCA1 and 2. In this review, we discuss HR deficiency hallmarks as predictive biomarkers for platinum salt and PARP inhibitor sensitivity for selecting patients affected by TNBC or epithelial ovarian cancer who could benefit from these therapeutic options.
Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal.umontpellier.fr/hal-02448191
Contributeur : Amandine Michel-Avella <>
Soumis le : mercredi 22 janvier 2020 - 10:24:25
Dernière modification le : jeudi 23 janvier 2020 - 01:32:29

Identifiants

Collections

Citation

Elodie Chartron, Charles Theillet, Séverine Guiu, William Jacot. Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data. Critical Reviews in Oncology/Hematology, Elsevier, 2019, 133, pp.58-73. ⟨10.1016/j.critrevonc.2018.10.012⟩. ⟨hal-02448191⟩

Partager

Métriques

Consultations de la notice

18